51 – 60 of 135
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Ten years with biologics: to whom do data on effectiveness and safety apply?
(
- Contribution to journal › Article
-
Mark
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison of UK, US and Danish utilities in south Swedish rheumatoid arthritis patients.
(
- Contribution to journal › Article
- 2010
-
Mark
Presence of peripheral arthritis and male sex predicting continuation of anti–tumor necrosis factor therapy in ankylosing spondylitis: An observational prospective cohort study from the South Swedish arthritis treatment group register
(
- Contribution to journal › Article
-
Mark
Rapid and sustained health utility gain in anti-TNF treated inflammatory arthritis. Observational data during seven years in southern Sweden.
(
- Contribution to journal › Article
-
Mark
Utility-based outcomes made easy: The number needed per QALY gained (NNQ). Observational cohort study from Southern Sweden of TNF blockade in inflammatory arthritis.
(
- Contribution to journal › Article
-
Mark
Elevated neutrophil membrane expression of proteinase 3 is dependent upon CD177 expression.
(
- Contribution to journal › Article
-
Mark
Prevalence and predictive factors of comorbidity in rheumatoid arthritis patients monitored prospectively from disease onset up to 20 years: lack of association between inflammation and cardiovascular disease.
(
- Contribution to journal › Article
-
Mark
Decrease in sick leave among patients with rheumatoid arthritis in the first 12 months after start of treatment with tumour necrosis factor antagonists: a population-based controlled cohort study.
(
- Contribution to journal › Article
-
Mark
Prevalence and incidence of rheumatoid arthritis in southern Sweden 2008 and their relation to prescribed biologics.
(
- Contribution to journal › Article
- 2009
-
Mark
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
(
- Contribution to journal › Article